The final objective of the ATAPoC project is to offer a disruptive technology for testing food allergies and immunological intolerances detection to make these tests more accessible for the end-user and the society at large.
In order to achieve reliable testing for food allergies and sensitivities, there is a common consensus in the scientific constituency about the importance of monitoring both IgEs (Immunoglobulins E) and IgGs (Immunoglobulins G). Although some of these tests are currently available in the market, the ATAPoC project proposes launching a more reliable technology based on disposable biosensors capable of measuring IgGs and IgEs on a single chip with ignificant better capabilities and much lower price.
This effort has ultimately lead to a more advanced device which is the base for the AllerScreening platform – see “AllerScreenig” under projects to learn more about it.
BiOD is participating in the design and integration of the different modules within the Chemical Detection Unit (CDU) up to the feasibility study for the final user. It includes the installation of the first CDU prototype and fabrication of the chip exchanging mechanism.
In this project we will experimentally test and validate a PoC device based on our technology for the simultaneous measurement of three biomarkers (proteins MMP9, S100A6 and CST4) associated with the ophthalmological pathology of dry eye.
This project intends to carry out a proof of concept of biod technology for its application to the detection of biomarkers related to Alzheimer’s disease (TAU and beta-amyloid protein).